The effect of oxidized low-density lipoprotein combined with adriamycin on the proliferation of Eca-109 cell line by Li, Hao et al.
RESEARCH Open Access
The effect of oxidized low-density lipoprotein
combined with adriamycin on the proliferation
of Eca-109 cell line
Hao Li
1*†, Qing D Li
1†, Ping Zhi Wang
2†, Mei Shu Wang
2†, Jia Cui
3†, Tao Yu Diao
3 and Qing Hui Li
3
Abstract
Background: The purpose of this study was to identify the affect on the proliferation Eca-109 cells treated with
oxidized low-density lipoprotein (ox-LDL) combined with adriamycin (ADM).
Methods: Eca-109 cell were cultured in the presence of oxLDL/ADM, and cell proliferation tested by MTT and cell
apoptosis was monitored by the proportion of apoptosis and cell cycle by flow cytomester. We simultaneously
evaluated the level of associated- apoptosis Bcl-2, Bax, and Caspase-3 gene mRNA and protein.
Results: OxLDL were cytotoxic and activate apoptosis. OxLDL combined with ADM significant enhanced the
proportion rate of apoptosis on a time and dose dependency. The expressions of the inhibiting apoptosis Bcl-2
gene mRNA and protein were down regulated, whereas, the expressions of the promoting apoptosis Bax, and
Caspase-3 genes mRNA and protein were up regulation.
Conclusion: These results suggested that oxLDL have cytotoxicity and activate apoptosis on the Eca-109 cells.
OxLDL combined with ADM have a synergistic effect on the apoptosis induced Eca-109 cells. Furthermore, oxLDL
may contribute to the improvement of clinical chemotherapy of cancer need to make further investigation.
Keywords: Esophagueal squamous cell line, low-density lipoprotein, adriamycin, apoptosis, gene, protein,
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Background
Nutrition therapy for patients with terminal cancer-
associated cachexia
Weight lost and muscle wasting is a major characteristic
of the cachexia associated with diverse pathologies such
as terminal cancers, bacterial sepsis, and AIDS [1].
According to recent findings, the progressive weight loss
and muscle wasting seen in cancer patients can be
halted or even reversed by giving them a high-energy
and high-protein supplement containing omega-3 fatty
acids [2]. Various experimental and clinical studies have
proved the benefit of consuming a diet supplemented
with high-quality proteins (rich in essential amino acids)
[3], omega-3 fatty acids [4,5], and antioxidants [6].
A current study reported that a crayfish enzymatic
extract (a diet formulated), which characterized by its
high contents in essential amino acids, omega-3 fatty
acids and carotenoids, used for the treatment of cancer-
associated cachexia in a rat model, and the results
showed it can increase the survival of tumor-bearing
animals and meliorate the cachexia symptoms - anorexia
and body mass loss (muscle and adipose tissue) [7,8].
Recently a work reported the result of preoperative
nutritional deficiency on mortality after radical cystect-
omy for bladder cancer ( nutritional deficiency, as mea-
sured by preoperative weight loss, body mass index and
serum albumin), is a strong predictor of 90-day mortal-
ity and poor overall survival [9].
Oxidized low- density lipoprotein (oxLDL) anti- tumor
Pathophysiologic effects of oxLDL in atherogenesis have
been established. Recent studies show an association
with tumorigenesis [10]. Oxidative stress is a term used
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reactive oxygen (ROS) and nitrogen (RNS) species and
the antioxidative defense mechanisms of the body [11].
ROS cause oxidation of lipids, proteins, and DNA in
vivo [12,13]. LDL is susceptible to oxidation, resulting in
the formation of oxLDL [14,15]. In recent years, there
have been many studies suggesting that excessive lipid
peroxidation may play a key role in cancer development
[16] Furthermore, it has been found in animal models
that a high level of lipid peroxidation is closely asso-
ciated with carcinogenesis [17,18].
Our previous study showed that oxLDL was decreased
in patients with esophageal squamous cell carcinoma
(ESCC). The decreasing oxLDL negatively relate to the
different stages of the development of esophageal squa-
mous cell carcinoma, which starts from normal epithe-
lium to basal cell hyperplasia, dysplasia or carcinoma in
situ and, finally, to invasive ESCC [19-21].
Given the results of these previous studies, we hypothe-
size that if patients with cancer were given nutrition ther-
apy, especially omega-3 fatty acids, in early stage, the
terminal cancer-associated cachexia would delay occurs.
The fact prompts us, a composition of lipids, such as
oxLDL, may be associated with tumor progression. The
aim of the present study was to investigate the role of
oxLDL and oxLDL combined with ADM (ADM) in Eca-
109 cell apoptosis. Through their pro-apoptotic effect
observed in vitro, oxLDL would enhance the efficiency of
inhibiting the proliferation of cancer cells treated by
ADM and thus might be considered as nutritional indica-
tor in the progression of ESCC.
Methods
Cell culture
Human ESCC cells, Eca-109, was supplied by the
Affiliated Hospital of Tumor Treatment and Prevention
of Shandong Academy of Medical Sciences repository
and cultured in RPMI1640 medium (Gibco, Los Angeles,
CA, USA) supplemented with 10% heat-inactivated new-
born calf serum (HangZhou Sijiqing Biological Engineer-
ing Materials Co. Ltd. China), and cells were grown in a
humidified incubator at 37°Cand 5%CO2.
Assay of in vitro oxLDL and ADM sensitivity
An enzyme-linked immunosorbent assay (ELISA) kits of
oxLDL purchased from ADL (Adliteram Diagnostic
Laboratories Lnc., USA). The 3-(4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazoliumbromide (MTT) assay [22]
was tested to calculate the inhibition rate of cell viability
treated by drugs. Briefly, the untreated Eca-109 cells
were generally in exponential growth phase at the end
of the 7-day incubation. All the results represented
the average of a minimum of 6 wells. The Eca-10
9 cells
were grown on a 96-well plate at 1 × 105 cells/ml in
complete RPMI 1640 medium.
Oxidized LDL and ADM were added at various differ-
ent drug concentrations. Eca-109 cells without drugs in
medium were used as the blank controls. After the
drugs treatment for 20 h, 44 h, and 68 h at 37°C, 20 μl
MTT were added into each well and incubated for a
further 4 h respectively, then the medium were removed
and 150 μl dimethyl sulfoxide were added to each well
to dissolve the formazan crystals. Absorbance values
were measured with spectrophotometer at the wave-
length of 570 nm.
The number of cells was also established using a
hemocytometer and the cell viability was determined by
the trypan blue exclusion test. The inhibition rate of cell
viability was calculated using the following formula:
Inhibition of cell viability = (1-average a value of experi-
mental group/average a value of control group) × 100%.
Assay of in vitro oxLDL combined with ADM sensitivity
Eca-109 cells were treated with 40 μg/ml oxLDL and
0.1 μg/ml ADM for 48 h. Cells were harvested by centri-
fugation, and then were tested by MTT to calculate the
inhibition rate as above description.
Determination of Eca-109 cell Apoptosis
Cell apoptosis assay by AnnexinV/PI
Twenty-four hours, 48 h and 72 h, after culture, cells
were trypsinized, counted1 × 10
6 cells per sample were
washed twice by ice-cold PBS solution, and then 5 μlo f
annexin V-FITC (AV) and 10 μl of propidium iodide
(PI) (Sigma) were added to 100 μlo fc e l ls u s p e n s i o n ,
followed by incubation for 15 min at room temperature
in the dark. Finally, 400 μl of binding buffer was added
to each sample, and filtered by 300-mesh nylon net
before EPICS XL (Beckman Coulter, Bren CA USA)
flow cytometer.EXPO32 ADC Analysis Software was
used to analyze the data.
Cell cycle analysis by flow Cytometry
Twenty-four hours, 48 h and 72 h, after culture, cells
were trypsinized, counted1 × 10
6 cells per sample were
washed twice by ice-cold PBS solution, and then fixed
with 70% ice-cold ethanol overnight at 4°C. Fixed cells
were washed twice with PBS and fixed with 70% ice-
cold ethanol overnight at 4°C. Fixed cells were washed
twice with PBS. Cellular DNA was stained with 500 μl
propidium iodide solution (0.005%PI, 0.1%Triton X-100,
0.1 mM EDTA,0.01%Rnase,0.1 ml PBS), followed by
incubation for 30 min at 4°C in the dark, and filtered by
300-mesh nylon net. Samples were analyzed on an
EPICS XL flow cytometer (Beckman Coulter, Bren CA
USA). The percentage of cells in each phase of the cell
cycle was estimated.
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In vitro total mRNA was extracted from the cells with
Trizol reagent (Invitrogen Co. California, USA) accord-
ing to manufacturer’s instructions. Single stranded
cDNA was synthesized by reverse transcription from 1
μg of total RNA using Reverse Transcriptase RNAse M-
MLV (Invitrogen Co. California, USA) and oligo-dT.
The amplification was performed in a final volume of 50
μl, containing 5 μl cDNA, 0.5 μl of each oligonucleotide
primer, 1 μlo fe a c hd N T P s ,a n d1u n i t so fT a qD N A
polymerase. Amplification was carried out in a Thermal
Cycler. All oligonucleotide primer sets used to measure
the expression levels of Bcl-1, Bax, Caspase-3 gene
mRNA, were previously described [11,17,23]. The pri-
mers used for measurements of the mRNA expression
levels of genes (upstream and downstream, respectively)
were CGACGACTTCTCCCGCCGCTACCGC and
CCGCATGCTGGGGCCGTACAGTTCC for Bcl-2
mRNA; TCCACCAAGAAGCTGAGCGAG and GTCCA
GCCCATGATGGTTCT for Bax mRNA; CCCATTTCT
CCATACGCACT and TGACAGCCAGTGAGACTTGG
for Caspase-3 mRNA; GTGGGGCGCCCCAGGCACC
and CTCCTTAATGTCACGCACGATTTC for b-actin
serves as loading control. Circulating condition: 94°C
one min, 58°C one min, 72°C one min, thirty cycles,
then 72°C prolong 7 min. End products were identified
by electrophoresis using 1.5% agarose gel.
Western blot analysis
Cells treated for 48 h as described above were washed
twice in ice-cold PBS and protein extracts of Eca-109
cells were prepared by lysis buffer (150 mM NaCl, 1%
NP-40, 0.5% 1nM Sodium orthorandate, 0.1% sodium
dodecyl sulfate (SDS), 50 mM Tris HCl, 10 mM EDTA,
a n d1m MP M S F )f o r3 0m i na t4 ° C .S a m p l e sw e r e
next centrifuged for 15 min at 10,000 g. Protein con-
centrations of supernatants were determined. For each
sample, 60 μg of protein was loaded on a 12.5% SDS-
polyacrylamide gel, electrophoresed, and transferred to
a nitrocellulose membrane (Protran; Schleicher and
Schuell, Florham Park, NJ). Each membrane was
blocked for 1 h at room temperature with blocking
buffer (TBS containing 0.1% Tween 20 and 5% milk
powder). Primary antibodies (applied for 1 h at room
temperature, or overnight at 4°C) were: anti-Bcl-2
(Santa Cruz Biotechnology, Inc., Heidelberg, Germany),
anti-Bax (Santa Cruz), and anti-actin (mouse monoclo-
nal C-2, Santa Cruz). Antibodies were diluted, there-
after, membranes were incubated for 1 h with HRP-
labeled secondary antibodies (Amersham Pharmacia
Biotech, Uppsala, Sweden), goat anti-rabbit, and the
blots were finally developed using an ECL Imaging
Densitometer (Amersham Bioscience, Buckingham-
shire, UK).
Microscopy
Morphological changes in cancer cells treated with
oxLDL and ADM were observed by the trypan blue
exclusion test using an Olympus microscope. During
the procedure, cell morphology was observed under
light microscope for different time.
Statistical Analyses
Statistical calculations were carried out with the SPSS
15.0 for Windows software package. Results are
expressed as the mean ± standard deviation of indepen-
dent experiments. Statistical differences between two
groups were calculated by the unpaired Student’s t-test;
and the differences among more than two groups were
tested by one-way ANOVA or two-way ANOVA, and
follow the Bonferroni test for sub- two groups compari-
son, P values < 0.05 were considered to be significant.
Results
OxLDL have cytotoxic effects on Eca 109 cell in vitro
The effect of oxLDL was examined in Eca 109 cell line.
OxLDL decreased cell viability and proliferation in a
dose- and time- dependent manner in the test (figure 1).
OxLDL induces apoptosis
The apoptotic frequencies of Eca-109 cells treated with
three concentrations (10, 40, 90 μg/ml) of oxLDL
increased in a dose- and time- dependent manner in the
flow cytometer test (figure 2).
Assay of in vitro oxLDL combined with ADM sensitivity
Compared with the viability rates of Eca-109 cell treated
by oxLDL or ADM alone, the viability rates of Eca-109
cells treated by oxLDL combined with ADM also
decreased along with a dose- and time- dependence.
The viability rates of Eca-109 cell treated by 40 μg/ml
oxLDL combined with 0.5 μg/ml ADM were signifi-
cantly lower than that in all other groups at 24 h, 48 h,
and 72 h after the treatment in the MTT test (figure 3).
Figure 1 The viability of Eca-109 cells treated with oxLDL in
the MTT test.
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Typical apoptosis morphological changes were found in
Eca-109 cell line 48 h after treatment with 40 μg/ml
oxLDL, 0.1 μg/ml ADM and both of them combined.
The changes included nuclear chromatin condensation
and fragmentation, plasmic budding, phagocytosis of the
extruded and apoptotic body (figure 4).
OxLDL combined with ADM induce the apoptosis and the
changes of cell cycle
Compared with the apoptotic frequency of Eca-109 cell
treated by 40 μg/ml oxLDL or 0.1 μg/ml ADM alone,
the apoptotic rate of Eca-109 cells treated by 40 μg/ml
oxLDL combined with 0.1 μg/ml ADM was significantly
higher in the flow cytometer test (figure 5).
The abilities of 40 μg/ml oxLDL or 0.1 μg/ml ADM
on alone or their combination to stimulate the Eca-109
cells into the cell cycle were analyzed by flow cytometry.
Cells treated with 40 μg/ml oxLDL or 0.1 μg/ml ADM
had substantial increases in the proportion of cells in S
phase over time. For example, after treatment with 40
μg/ml oxLDL, 29.86% of cells were in S at 48 h. After
treatment with 0.1 μg/ml ADM, 62.59% of cells were in
S phase at 48 h. In contrast, after treatment with both
of them combination, 75.66% of cells was in G2/M
blockage at 48 h (figure 5).
RT-PCR the expression of Bcl-2, Bax and caspase-3 genes
Forty eight hours After the Eca-109 cells treated with
oxLDL, ADM or their combination, the levels of Bcl-2
gene expression were down-regulated, while the levels of
Bax and caspase-3 genes expression were up-regulated,
compared with that in the control group (figure 6).
Protein expression of Bcl-2, Bax and caspase-3 genes in
West blot test
After 48 h of the Eca-109 cells treated with oxLDL,
ADM or their combination, the levels of protein expres-
sion of Bcl-2 gene decreased, while the levels protein
expression of Bax and caspase-3 genes increased, com-
pared with that in the control group (figure 7).
Discussion
It is well established that lipid-lipoprotein particles
among density classes are metabolically processed form-
ing a sequence of diminishing size and lipid distribution,
beginning with LPL activity on triglyceride in chylomi-
cron and continuing through HDL, resulting in increas-
ing density and loss of lipid due to enzymic activities
during the course of normal lipid transport [24]. Tumor
burden also resulted in a marked reduction in adipose
tissue, together with a clear hyperlipemia. The loss of
fat mass is the result of two altered processes: first, an
increase in lipolytic activity, which results in a signifi-
cant release of both glycerol and fatty acids [25], and
second, a marked decrease in the activity of lipoprotein
lipase (LPL). This enzyme is responsible for the cleavage
of both endogenous and exogenous triacylglycerols
to form glycerol and fatty acids, which is reflected as
hypertriglyceridemia [26].
Pathophysiologic effects of oxLDL in atherogenesis
have been established. Recent studies show a positive
Figure 2 The frequencies of apoptosis for Eca-109 cells treated
with three concentration (10, 40, 90 μg/ml) of oxLDL observed
after 24 h, 48 h and 72 h of the treatment. *: Compared with
the control, p < 0.05.
Figure 3 The frequencies of viability for the Eca-109 cell treated with oxLDL, ADM on alone or their combination. *: p < 0.05, **: p <
0.01 in ANOVA test.
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an increased risk of colon, breast and ovarian cancer
[27-29]. An earlier study reported that lipids might pri-
marily affect the gonads, and subsequently higher estra-
diol secretion could influence the development of
malignancies in these sites [30]. Later study showed that
it is possible that LDL, which is susceptible to oxidation,
result in high lipid peroxidation contributing to carcino-
genesis [27].
In the past years, there has been a growing body of evi-
dence that excessive lipid peroxidation may play a key
role in cancer development [31,32] and in animal model
Figure 4 Morphology of Eca-109 cell apoptosis in light microscopy (magnification with x100 and x400, respectively for the same
slice); When the Eca-109 cell treated with the drugs 48 h after the treatment, the morphology of the cell showed nuclear chromatin
condensation and fragmentation, plasmic budding, phagocytosis of the extruded and apoptotic body. Note: The doses of drugs treated with 40
μg/ml oxLDL, 0.1 μg/ml ADM, and both of them combined.
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Page 5 of 11Figure 5 A-1, B-1, C-1 and D-1 showed the distribution of percentages of apoptosis;, and A-2, B-2, C-2 and D-2 showed the
distribution of percentages of cell cycle for Eca-109 cells treated with oxLDL or ADM alone and both of them combined after 48 h of
the treatment. For cell cycle: A-2: 67.37 ± 5.49%, 22.03 ± 0.73% and 10.60 ± 0.26% in the G1/G0, S and G2/M phase of control; B-2: 59.45 ±
4.53%, 29.86 ± 1.77% and 10.69 ± 0.62% in the G1/G0, S and G2/M phase of the oxLDL; C-2: 24.12 ± 3.64%, 62.59 ± 4.29% and 13.28 ± 1.45% in
the G1/G0, S and G2/M phase of the ADM; D-2: 8.73 ± 2.48%, 15.61 ± 5.17% and 75.66 ± 3.64% in the G1/G0, S and G2/M phase of the above
oxLDL and ADM combined, respectively. The proportions of apoptosis and phase of cell cycle in 40 μg/ml oxLDL + 0.1 μg/ml ADM group were
significant higher than that in other groups, p < 0.05. Dose: A-1 and A-2: control group; B-1 and B-2:4 0μg/ml oxLDL; C-1and C-2: 0.1 μg/ml
ADM; D-1 and D-2:4 0μg/ml oxLDL + 0.1 μg/ml ADM. Abbreviation: ADM, adriamycin.
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metabolites damage DNA and can seriously inhibit DNA
repair capacity through their direct interaction with repair
proteins [34]. Circulating oxLDL is also quite reliable bio-
marker of lipid peroxidation [17]. OxLDL have been
reported as a potent independent mitogenic factor [35]
that induces proliferation or cell death [36] and further-
more, could contribute to the release of cytokines and
growth factors-associated with cancer [37]. However, a
meta-analysis on patients suffering from various diseases
revealed that only under severe pathological conditions, e.
g. HIV infection, all the indices of oxidative stress corre-
late with each other [38].
The present investigation, for the first time, identified
cytotoxicity on the proliferation of Eca-109 cell line and
showed time and dose dependency. The apoptosis of
Eca-109 cells treated by oxLDL also showed in time- and
dose- manner. The RT-PCR expression of Bcl-2, Bax and
caspase-3 genes mRNA and protein expression of them
confirmed the mechanism of the inducing apoptosis by
oxLDL. This fact suggests that the physiological amount
of oxLDL involves in the process of cell apoptosis, clears
the mutation cells or controls the proliferation of cancer
cells in vivo. At the advanced stage of cancer, the activity
of lipoprotein lipase in vivo decreases, and in conse-
quence, the level of oxLDL declines, promoting an
uncontrolled proliferation of tumor cell. Meanwhile, the
activity of lipolysis increases, leading to occurrences of
the cancer-associated cachexia.
It is confirmed that non-oxidized low-density lipopro-
tein (nLDL) has no effect on cell lines viability and prolif-
eration [35]. OxLDL with cytotoxicity or autophagy
dependences cell types. Under some conditions, oxLDL
can be cytotoxic. OxLDL can induce changes in cell cycle
protein distribution and expression characteristic of a
controlled, adaptive response to a chronic pathological
condition. Autophagy is another form of programmed
cell death mediated by the lectin-like oxLDL receptor-1
(LOX-1)-dependent [39]. Previous studies showed that
oxLDL (more than 10 μg/ml) has cytotoxic effects on
cancer cells in vitro and activate apoptosis and autop-
h a g y .O x L D L ,a p p l i e da tp h y s i o l o g i cc o n c e n t r a t i o n s ,
decreased cell viability and proliferation in a dose-depen-
dent manner in cell lines tested such as HT29 (colon),
OVCAR3 (ovarian), HeLa (cervical), MCF7 (breast), A549
(lung), and PC3 (prostate) [40]. However, when the quies-
cent human fibroblasts and rabbit smooth muscle cells
(VSMC) were treated with oxLDL at physiological ranges
(0, 10, or 50 μg/ml) at 24-48 h, the total cell number of
them significantly increased [35].
Now in another test, we also observed, the human
umbilical vein endothelial cells (HUVEC) was treated
with the dose lass than 40 μg/ml oxLDL at physiological
ranges for 24-48 h. The resulted in significant increases
in total HVEC cell counts at both time points. However,
when the cell treated with larger than 40 μg/ml oxLDL,
the inhibiting proliferation phenomenon observed at the
same time points for the cells (data not shown).
More than two decades ago, epidemiological studies
showed a U-shaped relationship between total choles-
terol (TC) levels and risk of all-cause mortality. The
relationship between the baseline serum cholesterol
level to total mortality was attributed to the high
Figure 6 The RT-PCR expression of Bcl-2, Bax and Caspase-3
gene mRNA for the Eca-109 cell treated by the oxLDL, ADM,
and both of them combined for 48 hours. b-actin serves as
loading control. Note: line 1: DNA marker; line 2: control; line 3: 40
μg/ml oxLDL; line 4: 0.1 μg/ml ADM; Line 5: 40 μg/ml oxLDL + 0.1
μg/ml ADM. Abbreviation: ADM, adriamycin.
Figure 7 The protein expression of Bcl-2, Bax and Caspase-3
genes for the Eca-109 cell treated with the oxLDL, ADM, and
their combination for 48 h. b-actin serves as loading control.
Note: line 1: control; line 2: 40 μg/ml oxLDL; line 3: 0.1 μg/ml ADM;
Line 4: 40 μg/ml oxLDL + 0.1 μg/ml ADM. Abbreviation: ADM,
adriamycin.
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level at the high end of the distribution (mainly due to
coronary heart disease) and at the low end (mainly due
to cancer) [41-43]. Recent study reported that in athero-
sclerosis, ox-LDL linkage with its receptor LOX-1 acti-
vates the inflammatory pathway through NF-B, leading
to cell transformation. LOX-1 is important for maintain-
ing the transformed state in developmentally diverse
cancer cell lines and for tumor growth, suggesting a
molecular connection between atherogenesis and tumor-
igenesis [10]. One study reported that low dose oxLDL
has bilateral adjustment characteristics on the prolifera-
tion of quiescent human fibroblasts and rabbit smooth
muscle cells. Western blot analysis revealed that oxLDL-
stimulated cell proliferation was associated with signifi-
cant increases in the expression of proteins that regulate
entry into and progression through the cell cycle. Sur-
prisingly, the expression of cell cycle inhibitors (p21 and
p27) was stimulated by oxLDL as well, but this was to a
lesser extent than the effects on cell cycle-activating
proteins [36]. In the present study, we also found, the
Eca-109 cells were treated with more than 40 μg/ml
oxLDL the cytotoxicity of it was significantly increase
on a time- and dose- dependency. It is possible that the
levels of oxLDL in vivo are dynamical changes based on
the body’s conditions. Under some condition, oxLDL
can be cytotoxic.
One clinical study indicated that the levels of oxLDL
were increased among both breast and ovarian cancer
patients as compared to the control subjects [44]. Another
previous study showed that fasting lipid and lipoprotein
studies on 38 consecutively diagnosed children with acute
lymphoblastic leukemia (ALL). The results showed that
the level of LDL decreased in the process of chemotherapy
of the malignant tumor and recovered to normal level
after the treatment. For those patients with ALL who had
a long-term survival, the normal levels of LDL also were
important [45]. The effects of tamoxifen treated the
patients with breast cancer showed that LDL particle dia-
meter correlated negatively with plasma triglyceride (TG)
(r = -0.62; p < 0.001). Tamoxifen-induced fatty liver in
breast cancer patients may be atherogenic, via increased
TG and consequent small, easily oxidized LDL particles
[46]. The smaller diameter of LDL particles, the more
easily oxidized into oxLDL.
Recent review the results of cancer-related malnutri-
tion patients with and without nutritional supplements
showed the weight loss is multifactorial but can be gen-
erally separated into two components. One component
included those outcomes that are the result of the meta-
bolic abnormalities as a direct consequence of the
tumor, and a second component including results of
treatments, psychological issues, and others. For people
with cancer the implement nutrition interventions are
effective, but there is no clarity in best options for nutri-
tion management [47]. More clinical observation of the
dynamic changes of oxLDL for other type cancer in che-
motherapy need to be confirm in future.
Another major finding of the present study is a syner-
gistic effect on inducing apoptosis of Eca-109 cells trea-
ted by the combination of 40 μg/ml oxLDL and 0.1 μg/
ml ADM. The proportion rate of apoptosis ECA-109
cells treated with their combination significantly
increased (19.79 ± 1.32), compared with that 40 μg/ml
oxLDL (15.11 ± 0.61), 0.1 μg/ml ADM (11.27 ± 0.54).
As well known, the chemical-therapy drugs of cancer,
such as ADM, have toxicity, if oxLDL combined with
the cytotoxic drugs could use in the clinic, may be more
benefit for the patient’s therapy. Further studies are
required in order to elucidate whether oxLDL play a
causative or merely consequential role in cancer process
and to designate a novel approach in the combination
therapeutic strategies.
Conclusion
These results suggested that oxLDL have cytotoxicity on
the proliferation of Eca-109 cell line and showed time
and dose dependency. OxLDL combined with ADM
have a synergistic effect on the apoptosis induced Eca-
109 cells. Furthermore, oxLDL may contribute to the
improvement of clinical chemotherapy of cancer need to
make further investigation.
Abbreviations
oxLDL: oxidized low- density lipoprotein; ELISA: enzyme-linked
immunosorbent assay; MTT: 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazoliumbromide; ESCC: esophageal squamous cell carcinoma;
ADM: adriamycin.
Acknowledgements
This study was supported by the Project of National Natural Science
Foundation of China (No.30571601 and No.30600258) and the 2006 Doctor
Fund Projects of Shandong Province, China (No. 2006BS03061).
Author details
1Qilu Hospital, Shandong University, Jinan, P.R. China.
2College of Public
Health, Shandong University, Jinan, P.R. China.
3Institutes of Basic Medicine,
Shandong Academy of Medical Sciences Jinan, P.R. China.
Authors’ contributions
Members listed below made their respective contributions to this
manuscript. Professor HL, QDL, PZW, MSW and JC designed the skeleton of
this study, performed cell proliferation and apoptosis, expression of gene
and protein and drafted the manuscript (they made the same contribution
to this work). TYD and QHL carried out the data analysis and checked the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 12 May 2011 Accepted: 29 June 2011 Published: 29 June 2011
References
1. Cohen J, Lefor AT: Nutrition support and cancer. Nutrition 2001,
17:698-699.
Li et al. Lipids in Health and Disease 2011, 10:108
http://www.lipidworld.com/content/10/1/108
Page 8 of 112. Silver S: EPA halts cancer-induced weight loss. Lancet Oncol 2000, 3:7.
3. May PE, Barber A, D’Olimpio JT: Reversal of cancer related wasting using
oral supplementation with a combination of beta-hydroxy-
betamethylbutyrate, arginine, and glutamine. Am J Surg 2002,
183:471-479.
4. Barber MD, Fearon KCH, Ross JA: Eicosapentaenoic acid modulates the
immune response but has no effect on a mimic of antigen-specific
responses. Nutrition 2005, 21:588-593.
5. Burns CP, Halabi S, Clamon GH: Phase I clinical study of fish oil fatty acid
capsules for patients with cancer cachexia: cancer and leukemia group
B study 9473. Clin Cancer Res 1999, 5:3942-3947.
6. Comi D, Baronzio GF, Vecchio C, Zambelli A, Cargnel A, Ferrario R,
Galante F, Barlocco A, Pravettoni G: Oxygen radicals, antioxidant vitamins
and minerals in AIDS cachexia. Nutrition 1997, 13:272.
7. Cremades O, Parrado J, Jover M, de Tera’n LC, Gutie’rrez JF, Palomas JDB:
Nutritional treatment of cancer cachexia in rats –Use of a diet
formulated with a crayfish enzymatic extract. Eur J Nutr 2007, 46:347-353.
8. Capra S, Bauer J, Davidson W, Ash S: Nutritional therapy for cancer-
induced weight loss. Nutr Clin Pract 2002, 17:210-2213.
9. Gregg JR, Cookson MS, Phillips S, Salem S, Chang SS, Clark PE, Davis R,
Stimson CJ, Aghazadeh JM, Smith JA, Barocas DA: Effect of Preoperative
Nutritional Deficiency on Mortality After Radical Cystectomy for Bladder
Cancer. J Urology 2011, 185:90-96.
10. Lu J, Mitra S, Wang X, Khaidakov M, Mehta JL: Contribution of Oxidative
Stress and Lectin-like OxLDL-receptor LOX-1 in Atherogenesis and
Tumorigenesis. Antioxid Redox Signal 2011.
11. Dotan Y, Lichtenberg D, Pinchuck I: Lipid peroxidation cannot be used as
a universal criterion of oxidative stress. Prog Lipid Res 2004, 43:200-227.
12. Saintot M, Astre C, Pujol H, Gerber M: Tumor progression and oxidant-
antioxidant status. Carcinogenesis 1996, 17(6):1267-1271.
13. Guyton KZ, Kensler TW: Oxidative mechanisms in carcinogenesis. Br Med
Bull 1993, 49:523-544.
14. Ray G, Husain SA: Role of lipids, lipoproteins and vitamins in women
with breast cancer. Clin Biochem 2001, 34:71-76.
15. Ray G, Batra S, Shukla NK, Deo S, Raina V, Ashor S, Husain SA: Lipid
peroxidation, free radical, and antioxidant status in breast cancer. Breast
Cancer Res Treat 2000, 59:163-170.
16. Uchida K: 4-hydroxy-2-nonenal: a product and mediator of oxidative
stress. Prog Lipid Res 2003, 42:318-343.
17. Chung FL, Nath RG, Ocando J, Nishikawa A, Zhang L: Deoxyguanosine
adducts of t-4-hydroxy-2-nonenal are endogenous DNA lesions in
rodents and humans: detection and potential sources. Cancer Res 2000,
60:1507-1511.
18. Sonoda I, Imoto I, Inoue J, Shibata T, Shimada Y, Chin K, Imamura M,
Amagasa T, Gray JW, Hirohashi S, Inazawa J: Frequent silencing of low
density lipoprotein receptor-related protein 1B (LRP1B) expression by
genetic and epigenetic mechanisms in esophageal squamous cell
carcinoma. Cancer Res 2004, 64:3741-3747.
19. Yang YF, Li H, Xu XQ, Diao YT, Fang XF, Wang Y, Zhao DL, Wu K, Li HQ: An
expression of squamous cell carcinoma antigen 2 in peripheral blood
within the different stages of esophageal carcinogenesis. Dis Esophagus
2008, 21:395-401.
20. Wang Yan, Li Hao, Diao Yutao, Li Hui-qing, Zhang Yukun, Yin Chang,
Cui Yongchun, Ma Qing, Fang Xueqiang, Zhou Yingzhi, Yang Yanfang:
Relationship between oxidized LDL antibodies and different stages of
esophageal carcinogenic progressionAcknowledgements. Archives of
Medical Research 2008, 39:760-767.
21. Diao YT, Li H, Li HQ, Zhou YZ, Ma Q, Wang Y, Li D: Association of serum
levels of lipid and its novel constituents with the different stages of
esophageal carcinoma. Lipids in Health and Disease 2009, 8:48-50.
22. Hida T, Ueda R, Takahashi T, Watanabe H, Kato T, Suyama M, Sugiura T,
Ariyoshi Y, Takahashi T: Chemosensitivity and radiosensitivity of small cell
lung cancer cell lines studied by a newly developed 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) hybrid
assay. Cancer Res 1989, 49:4785-4790.
23. Manoharan S, Kolanjiappan K, Kayalvizhi M: Enhanced lipidperoxidation
and impaired enzymic antioxidant activities in theerythrocytes of
patients with cervical carcinoma. Cell Mol Biol Lett 2004, 9:699-707.
24. Warnick GR, Knopp RH, Fitzpatrick V, Branson L: Estimating low-density
lipoprotein cholesterol by the Friedewald equation is adequate for
classifying patients on the basis of nationally recommended cutpoints.
Clin Chem 1990, 36:15-9.
25. Argile’s JM, A ‘ lvarez B, Lo’pez-Soriano FJ: The metabolic basis of cancer
cachexia. Med Res Rev 1997, 175:477-498.
26. Fried SK, Zechner R: Cachectin/tumor necrosis factor decreases human
adipose tissue lipoprotein lipase mRNA levels, synthesis, and activity. J
Lipid Res 1989, 30:1917-1923.
27. Delimaris I, Faviou E, Antonakos G, Stathopoulou E, Zachari A, Dionyssiou-
Asteriou A: Oxidized LDL, serum oxidizability and serum lipid levels in
patients with breast or ovarian cancer. Clin Biochem 2007, 40:1129-1134.
28. Suzuki K, Ito Y, Wakai K, Kawado M, Hashimoto S, Toyoshima H, Kojima M,
Tokudome S, Hayakawa N, Watanabe Y, Tamakoshi K, Suzuki S, Ozasa K,
Tamakoshi A, Japan Collaborative Cohort Study Group: Serum oxidized
low-density lipoprotein levels and risk of colorectal cancer: A case-
control study nested in the Japan collaborative cohort study. Cancer
Epidemiol Biomarkers Prev 2004, 13:1781-1787.
29. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G,
Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW: Effects of ligand
activation of peroxisome proliferator- activated receptor gamma in
human prostate cancer. Proc.Natl Acad Sci USA 2000, 97:10990-10995.
30. Stepsenwol J: Carcinogenic effect of cholesterol in mice. Proc Soc Exp Biol
Med 1966, 121:168-171.
31. Guyton KZ, Kensler TW: Oxidative mechanisms in carcinogenesis. Br Med
Bull 1993, 49:481-483.
32. Uchida K: 4-hydroxy-2-nonenal: a product and mediator of oxidative
stress. Prog Lipid Res 2003, 42:318-343.
33. Sanchez-Perez Y, Carrasco-Legleu C, Garcia-Cuellar C, Perez-Carreon J,
Hernandez-Garcia S, Salcido-Neyoy M, Alemán-Lazarini L, Villa-Treviño S:
Oxidative stress in carcinogenesis. Correlation between lipid
peroxidation and induction of preneoplastic lesions in rat
hepatocarcinogenesis. Cancer Lett 2005, 217:25-32.
34. Wiseman H, Halliwell B: Damage to DNA by reactive oxygen and nitrogen
species; role in inflammatory disease and progression to cancer. Biochem
J 1996, 313:17-19.
35. Zettler ME, Prociuk MA, Austria JA, Massaeli H, Zhong G, Pierce GN: oxLDL
stimulates cell proliferation through a general induction of cell cycle
proteins. J Am Physiol Heart Circ Physiol 2003, 284:H644-53.
36. Han CY, Pak YK: Oxidation-dependent effects of oxidized LDL
proliferation or cell death. Exp Mol Med 1999, 31:165-73.
37. Motta M, Pistone G, Franzone AM, Romeo MA, Di Mauro S, Giugno L,
Ruello P, Malaguarnera M: Antibodies against ox-LDL serum levels in
patients with hepatocellular carcinoma. Panminerva Med 2003, 45:69-73.
38. Kontush A, Spranger T, Reich A, Djahansouzi S, Karten B, Braesen JH,
Finckh B, Kohlschütter A, Beisiegel U: Whole plasma oxidation assay as a
measure of lipoprotein oxidizability. BioFactors 1997, 6:99-109.
39. Scoles DR, Xu X, Wang H, Tran H, Taylor-Harding B, Li A, Karlan BY: Liver X
receptor agonist inhibits proliferation of ovarian carcinoma cells
stimulated by oxidized low density lipoprotein. Gynecol Oncol 2010,
116:109-116.
40. Zabirnyk O, Liu W, Khalil S, Sharma A, Phang JM: Oxidized low-density
lipoproteins upregulate praline oxidase to initiate ROS-dependent
autophagy. Carcinogenesis 2010, 31:446-454.
41. Ginter E: Blood cholesterol levels and mortality in cancer. Bratisl Lek Listy
1990, 91:70-76.
42. Tamakoshi A, Ohno Y, Suzuki S, Kawamura T, Wakai K, Nakamura R:
Epidemiological remarks on low serum cholesterol level and cancer risk
of all sites. Nippon Koshu Eisei Zasshi 1994, 41:393-403.
43. Karvonen J, Päivänsalo M, Kesäniemi YA, Hörkkö S: Circulation
Immunoglobulin M type of autoantibodies to oxidized low-density
lipoprotein has an inverse relation to carotid artery atherosclerosis.
Circulation 2003, 108:2107-2112.
44. Delimaris I, Faviou E, Antonakos G, Stathopoulou E, Zachari A, Dionyssiou-
Asteriou A: Oxidized LDL, serum oxidizability and serum lipid levels in
patients with breast or ovarian cancer. Clin Biochem 2007, 40:1129-1134.
45. Parsons SK, Skapek SX, Neufeld EJ, Kuhlman C, Young ML, Donnelly M,
Brunzell JD, Otvos JD, Sallan SE, Rifai N: Asparaginase-associated lipid
abnormalities in children with acute lymphoblastic leukemia. Blood 1997,
89(6):1886-1895.
46. Wakatsuki A, Ogawa Y, Saibara T, Okatani Y, Fukaya T: Size and oxidative
susceptibility of low-density lipoprotein particles in breast cancer
Li et al. Lipids in Health and Disease 2011, 10:108
http://www.lipidworld.com/content/10/1/108
Page 9 of 11patients with tamoxifen-induced fatty liver. J Clin Endocrinol Metab 2002,
87:3676-3681.
47. Capra Sandra, Bauer Judith, Davidson Wendy, Susan Ash: Nutritional
Therapy for Cancer-Induced Weight Loss. Nutrition in Clinical Practice
2002, 17:210-213.
doi:10.1186/1476-511X-10-108
Cite this article as: Li et al.: The effect of oxidized low-density
lipoprotein combined with adriamycin on the proliferation of Eca-109
cell line. Lipids in Health and Disease 2011 10:108.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Li et al. Lipids in Health and Disease 2011, 10:108
http://www.lipidworld.com/content/10/1/108
Page 10 of 11Li et al. Lipids in Health and Disease 2011, 10:108
http://www.lipidworld.com/content/10/1/108
Page 11 of 11